The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers

Ihbe-Heffinger, Angela; Ehlken, B; Bernard, R; Berger, Karin; Peschel, Christian; Eichler, Hans‐Georg; Deuson, Robert; Thödtmann, J.; Lordick, Florian

doi:10.1093/annonc/mdh110

Cited by 118 publications

(127 citation statements)

References 15 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…It occurs either as a result of reduced plasma concentration or inefficacy of ongoing oral antiemetic medication. [2][3][4] A new formulation of a 5HT 3 RA (granisetron) delivered by transdermal route has been approved or made available in 12 countries and regions consisting of USA, Denmark, Finland, Germany, Italy, Netherlands, Norway, Sweden, UK, Taiwan, Hong Kong, and Singapore. Granisetron transdermal system (GTS) was developed to maintain effective plasma concentration for several days after chemotherapy.…”

Section: 21-24mentioning

confidence: 99%

“…GTS is the only antiemetic in the 5HT 3 RA group that can be used by patients unable or unwilling to use the oral or parenteral route. GTS can avoid venous manipulation required in chemotherapy, especially multiday.…”

Section: Patient Preferencementioning

confidence: 99%

“…-MEC: Use a two-drug regimen combining 5HT 3 RA and dexamethasone to prevent acute CINV and either one of three drugs for delayed CINV.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting

Kitayama

2016

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Serotonin-type 3 receptor antagonists have been available as intravenous and oral formulations. Recently, granisetron transdermal system has won a firm position in the antiemesis of cancer chemotherapy. Its pharmacokinetic profile has been shown by pooled population analysis incorporation data. The 52 cm2 patch, which contains 34.3 mg granisetron, releases 3.3 mg daily and reaches the maximal plasma concentration after 48 hours, maintaining a 2.2 ng/mL stable average concentration over six days. This level is similar to the one obtained with daily oral 2 mg of granisetron. Three randomized clinical studies evaluating its efficacy have been published. Transdermal granisetron showed noninferiority to other formulations of serotonin-type 3 receptor antagonists for highly and moderately emetogenic – including multiday – chemotherapy. The adverse effects were not significantly different from other formulations. The system has possible applications in oral chemotherapy, radiotherapy, dexamethasone sparing, palliative care, and refractory emesis due to benign disease.

show abstract

Section: 21-24mentioning

confidence: 99%

Section: Patient Preferencementioning

confidence: 99%

See 1 more Smart Citation

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting

Kitayama

2016

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

show abstract

“…Benché la quantificazione dei costi e dell'impatto di CINV nella pratica clinica sia di estrema importanza per l'allocazione delle risorse nei confronti di nuove terapie antiemetiche, gli studi che trattano il costo di malattia sono abbastanza ridotti [16][17][18][19][20] parte dei lavori tende a prendere in esame gli aspetti farmacoeconomici di un singolo antiemetico, e spesso solo in relazione alla CINV in fase acuta. L'unico studio specifico che ha valutato il costo di malattia nella realtà italiana che siamo riusciti a reperire è il lavoro di Ballatori e coll.…”

Section: Costo DI Malattiaunclassified

“…Per il palonosetron, i risultati derivano dagli studi registrativi, presi singolarmente o aggregati mediante tecniche meta-analitiche nel caso delle terapie moderatamente emetogene. Per i comparators, l'estrazione dei dati di efficacia utilizzati nel modello è avvenuta con tecniche più eterogenee: l'efficacia dei 5-HT 3 antagonisti nella prevenzione di CINV dopo HEC è derivata da uno studio osservazionale multicentrico condotto in Germania [16]; per l'efficacia preventiva dopo MEC è stata utilizzata la media ponderata dei risultati di quattro diversi trial per quanto riguarda lo schema che prevede sia la somministrazione parenterale in prima giornata sia quella orale nei giorni successivi, mentre è stato utilizzato il risultato ottenuto nel ramo di controllo degli studi registrativi del palonosetron per quanto riguarda lo schema con la sola terapia parenterale. La scelta dei dati di efficacia, chiaramente condizionata dalla letteratura disponibile, si presta tuttavia a qualche dubbio sulla omogeneità dei pazienti arruolati e delle tecniche profilattiche impiegate nei vari studi.…”

Section: Costo/efficaciaunclassified

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects

Pradelli

Eandi

2007

View full text Add to dashboard Cite

Despite considerable improvements in the last two decades, chemotherapy-induced nausea and vomiting (CINV) remains a frequent and very bothersome medical problem. It is estimated that about one half to two thirds of all chemotherapy-treated patients experience CINV, the frequency depending on the chemotherapy regimen used and on patient-specific features. The impact of CINV, which may be acute, delayed or even anticipatory in experienced patients, on health-related quality of life (HRQoL) is substantial in all domains. Until recently, effective treatment choices included corticosteroids and first-generation 5-HT 3 antagonists, which have been supported by aprepitant, the first clinically available NK1 antagonist, and by palonosetron, considered the first second-generation 5-HT 3 antagonist for its high receptor-subtype selectivity and affinity and long plasmatic half-life. In this paper, clinical pharmacology of the latter drug is briefly outlined and recent Italian papers on the epidemiology and HRQoL impact of CINV are reviewed, as well as national pharmacoeconomic evalutations conducted on palonosetron. The role in therapy of palonosteron and its potential for improved clinical, HRQoL and economic outcomes is discussed. Keywords: chemotherapy-induced nausea and vomiting (CINV), HRQoL, palonosetronPalonosetron nella prevenzione della CINV in Italia: aspetti farmacologici clinici e farmacoeconomici Lorenzo Pradelli (1) , Mario Eandi (2) Farmeconomia e percorsi terapeutici 2007; 8(2): 71-80dalla somministrazione della chemioterapia. Nausea e vomito sono in genere di intensità maggiore nelle prime 5-6 ore;ritardati: insorgono dopo almeno 24 ore dalla somministrazione (quindi il secondo giorno) e durano fino a 5-7 giorni. La frequenza degli attacchi può essere addirittura maggiore rispetto a quella osservata il giorno stesso del trattamento chemioterapico;anticipatori: si manifesta nel giorno o nelle ore che precedono la chemioterapia. La corretta gestione della CINV, essenzialmente rappresentata da un adeguata profilassi, riveste un'importanza estrema per fornire al paziente maggior benessere e per consentire una maggiore aderenza alla terapia. È cruciale che la profilassi venga attuata con i farmaci più efficaci e adeguati allo schema chemioterapico già dal primo ciclo, in quanto l'esperienza di emesi e nausea è di per sé un fattore favorente lo sviluppo di CINV ritardato nei cicli successivi [1].La patogenesi della CINV non è completamente chiarita e coinvolge probabilmente molti differenti siti d'azione, anche in funzione del particolare agente chemioterapico utilizzato --La nausea e il vomito indotti da chemioterapia (Chemotherapy-induced nausea and vomiting, CINV) sono tra gli effetti collaterali più comuni e gravosi correlati alla terapia antineoplastica. Circa i tre quarti di tutti i pazienti sottoposti a chemioterapia ne soffrono. L'incidenza di questi sintomi dipende in gran parte dal farmaco antineoplastico scelto e dal suo dosaggio; il cisplatino, ad esempio, uno dei chemioterapici più frequen...

show abstract

Employment benefits and job retention: evidence among patients with colorectal cancer

et al. 2018

View full text Add to dashboard Cite

A “health shock,” that is, a large, unanticipated adverse health event, can have long‐term financial implications for patients and their families. Colorectal cancer is the third most commonly diagnosed cancer among men and women and is an example of a specific health shock. We examined whether specific benefits (employer‐based health insurance, paid sick leave, extended sick leave, unpaid time off, disability benefits) are associated with job retention after diagnosis and treatment of colorectal cancer. In 2011–14, we surveyed patients with Stage III colorectal cancer from two representative SEER registries. The final sample was 1301 patients (68% survey response rate). For this study, we excluded 735 respondents who were not employed and 20 with unknown employment status. The final analytic sample included 546 respondents. Job retention in the year following diagnosis was assessed, and multivariable logistic regression was used to evaluate associations between job retention and access to specific employment benefits. Employer‐based health insurance (OR = 2.97; 95% CI = 1.56–6.01; P = 0.003) and paid sick leave (OR = 2.93; 95% CI = 1.23–6.98; P = 0.015) were significantly associated with job retention, after adjusting for sociodemographic, clinical, geographic, and job characteristics.

show abstract

The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers

Cited by 118 publications

References 15 publications

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects

Employment benefits and job retention: evidence among patients with colorectal cancer

Contact Info

Product

Resources

About